NFKB1 and B-cell chronic lymphocytic leukemia: BAFF-BAFF-R-mediated activation of non-canonical NF-κB signaling remains elevated despite ibrutinib treatment; hence, the combination of ibrutinib and VAY-736 exerts a synergistic response against CLL.